← Home / Corvus Pharmaceuticals, Inc. (CRVS)
Stock Analysis
Corvus Pharmaceuticals, Inc. (CRVS)
CRVS
CRVS · Market data
12.00 +2.21%
52W Range Position
38%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-06-18 13:43 UTC
WOI Investment Thesis
Mixed
Confirmation improves above 13.29. Holding above 11.99 keeps the current thesis intact.
⚖️
Fundamentals
Insufficient / Insufficient
Price Structure
Mixed
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Elevated
Analysis Scope
1Y Daily
Key Decision Levels
Hold Above
Structure remains valid above support.
11.99
Break Above
Confirmation improves above resistance.
13.29
🎯
Next Objective
Pattern-derived target if setup continues.
×
Thesis Break
Scenario weakens below invalidation.
Below 11.99
What's Driving CRVS?
📈 Technical recovery is improving
Momentum is Neutral. Watch 13.29 for confirmation and 11.99 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 11.99 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
No confirmed breakout yet. Watch the next level and momentum behavior.
Breakout Watch
Downtrend line not broken yet · score 0
Watch Level
15.06
RSI(14)
44.4
How to read this setup
The nearest decision zone is framed by support around 11.99 and resistance near 13.29. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup. Pattern-based invalidation is near 20.29; losing that area would weaken the active formation considerably.
Price Chart
CRVS · WOI overlay chart
Open Full Workspace
Business Lens
Financial context is mixed
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
Revenue Growth
Insufficient
Profitability
Insufficient
Cash Flow
Mixed
Balance Sheet
Manageable
📈 Net Income
-13.69M
≈ Insufficient
🧮 EPS (Basic)
-0.15
≈ Insufficient
Corvus Pharmaceuticals, Inc.
Note: This is an algorithmic technical snapshot, not financial advice.